Chasteberry (Vitex agnus-castus).

Chasteberry acts on pituitary dopamine receptors to support normal prolactin regulation, and vitamin B6 is a cofactor the body uses in dopamine synthesis, so the two touch the same signalling pathway. The pair is a long-standing combination in cyclic women's support formulas.

Chasteberry acts on dopamine D2 receptors in the pituitary to modulate prolactin, while black cohosh triterpene glycosides act on serotonergic and receptor-level signalling.

Dong quai contributes coumarins and ferulic acid affecting smooth muscle tone and circulation, a separate mechanism from the dopaminergic prolactin modulation chasteberry provides.

Magnesium relaxes smooth muscle and is the cofactor for the B6-dependent decarboxylases that make dopamine and serotonin, the same neurotransmitter axis chasteberry works on.

GLA feeds the series-one prostaglandin route that governs tissue sensitivity to prolactin, so it complements chasteberry acting on prolactin release itself.

St John's wort acts on monoamine reuptake while chasteberry works through pituitary dopamine signalling, so the two act from separate directions in one of the most frequently combined pairs in this category.

Shatavari steroidal saponins are traditionally used with mild galactogogue action, which sits opposite chasteberry's prolactin-lowering direction, so the balance in a formula matters.

Red clover isoflavones bind estrogen receptors weakly at the tissue level, while chasteberry works upstream at the pituitary. Receptor-level and axis-level actions in one formula.

Maca glucosinolates and macamides act on the hypothalamic-pituitary axis without binding hormone receptors directly, a complementary route alongside chasteberry's dopaminergic action.

Inositol serves as the second messenger for FSH and insulin signalling in the ovary, downstream of the pituitary axis chasteberry modulates.

Mucuna supplies L-dopa, which raises dopamine directly, and chasteberry diterpenes are D2 receptor agonists, so their effects on pituitary prolactin release stack. Worth flagging when both appear in one formula.

Calcium D-glucarate inhibits beta-glucuronidase in the gut, so glucuronidated hormone conjugates stay conjugated and leave the body rather than being reabsorbed. It works on clearance while chasteberry works on release.

DIM acts on hepatic oestrogen hydroxylation, shifting the balance of oestrogen metabolites, while chasteberry acts higher up at the pituitary through dopamine receptor binding. The two touch different points of the same axis rather than duplicating each other. No combination study grounds the pairing.

Sulforaphane induces phase II conjugating enzymes that handle steroid hormone metabolites, a clearance-side action distinct from chasteberry's pituitary effect. Formulators combine an upstream signal modulator with a downstream clearance support on that logic. The pairing is mechanistic, not measured.

Steroid hormones are conjugated and cleared hepatically, and silymarin is used in formulas aimed at that conjugation step. Chasteberry works at the pituitary end instead. Read the combination as complementary positioning within one axis rather than as a demonstrated interaction.

EPA and DHA compete with arachidonic acid as substrate for cyclooxygenase, shifting the eicosanoid profile that governs uterine smooth muscle tone across the cycle. Chasteberry does not act on that pathway at all. The two are combined for coverage of different mechanisms, with no combination data here.

Vitamin D receptors are expressed in reproductive tissue and vitamin D status is bound up with normal steroid hormone signalling. Products pair it with chasteberry for that reason. This is a receptor-distribution observation rather than evidence that the two work better together.

Zinc is a structural component of the nuclear receptors that steroid hormones act through, and it is a cofactor across steroidogenic enzymes. That role is settled biochemistry independent of chasteberry. The combination itself has not been tested.

Menstrual blood loss is the main route of iron loss in women of reproductive age, so iron status and cycle-focused formulas are routinely addressed together. Chasteberry has no effect on iron absorption or handling. The pairing is nutritional context, not a mechanistic interaction.

Ashwagandha is used for the adrenal stress axis while chasteberry acts on pituitary prolactin signalling, two arms of the same neuroendocrine system. Traditional and commercial formulas combine them. There is no combination trial behind it.

Both are placed in stress-and-cycle formulas, rhodiola for monoamine turnover and chasteberry for its dopaminergic action at the pituitary. The overlap is at the level of monoamine signalling. The rationale is mechanistic and the pairing untested.

Chamomile has a long history in cycle-comfort preparations and contributes apigenin, which binds benzodiazepine sites in vitro. It is combined with chasteberry in traditional European formulations. Read the pairing as traditional practice rather than clinical evidence.

Lemon balm is used alongside chasteberry in calm-and-cycle formulas, contributing rosmarinic acid and a GABA transaminase inhibiting action described in vitro. The two do not share a mechanism. The combination rests on formulation tradition.

Theanine influences glutamate and GABA signalling and raises alpha wave activity, a different target from chasteberry's pituitary dopamine receptors. They are combined for breadth in calm-focused cycle formulas. No data describe the two together.

Chasteberry diterpenes bind dopamine D2 receptors directly, whereas tyrosine supplies substrate for dopamine synthesis. One acts at the receptor and the other at the precursor pool, so their effects are not additive in any simple way. This is a mechanistic observation and the direction of any net effect is unknown.

Melatonin and prolactin secretion are both entrained to the sleep-dark cycle through hypothalamic and pituitary signalling. Chasteberry acts on the prolactin side of that arrangement. The overlap is circadian and neuroendocrine, and no study has examined the two together.

Tocopherols appear alongside chasteberry in long-standing cycle-comfort formulations, contributing lipid-phase antioxidant capacity. The two mechanisms do not intersect. Count it as formulation convention.